To assess the pathophysiological relevance of the RB/E2F/ACSL4 axis in human prostate cancer, we utilized 4 publicly available data sets of metastatic castration-resistant prostate cancer from cBioportal (39) to determine whether RB1 loss/E2F activation is associated with the expression of the ferroptosis regulator ACSL4. Here, ACSL4 is linked to prostate cancer.